Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolution of oligoleukemia.

B Barlogie, D A Johnston, M Keating

    Cancer
    |May 15, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

    Leukemia·2018
    Same author

    Drug response prediction in high-risk multiple myeloma.

    Gene·2017
    Same author

    Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

    Nature communications·2017
    Same author

    Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

    Leukemia·2017
    Same author

    NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

    Leukemia·2017
    Same author

    Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

    Blood cancer journal·2017

    Lithium treatment did not improve outcomes for patients with oligoleukemia. Pre-treatment factors predicted progression to acute leukemia, which had a better survival than marrow failure.

    Area of Science:

    • Hematology
    • Oncology
    • Pharmacology

    Background:

    • Oligoleukemia is a pre-leukemic condition.
    • Understanding its progression is crucial for patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy of chronic lithium administration in oligoleukemia.
    • To identify predictors of oligoleukemia progression.

    Main Methods:

    • 22 patients with oligoleukemia received chronic lithium.
    • Pre-treatment characteristics were analyzed for correlation with disease evolution.

    Main Results:

    • Lithium did not alleviate cytopenia or stimulate bone marrow activity.
    • Higher leukemic infiltrate, normal myeloid precursors, platelet count, and female sex predicted progression to overt leukemia.

    Related Experiment Videos

  • Progression to overt leukemia was associated with longer survival than marrow failure.
  • Survival in overt leukemia inversely correlated with leukemic infiltrate.

    • Conclusions:

    • Lithium is ineffective for oligoleukemia.
    • Predictive factors for oligoleukemia progression were identified.
    • Oligoleukemia may represent a differentiated leukemia with specific cellular abnormalities.